Research recommendations coming out of this guidance The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision? Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example, glucagon‑like peptide‑1 [GLP‑1] mimetics and insulin combination therapy with meglitinides) are most effective when initial drug treatment with non‑metformin monotherapy fails to adequately control blood glucose levels? Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides? Self-monitoring of blood glucose levels: What is the optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes? Effectiveness of SGLT2 inhibitors for different ethnic groups: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups? Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?
The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?
Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example, glucagon‑like peptide‑1 [GLP‑1] mimetics and insulin combination therapy with meglitinides) are most effective when initial drug treatment with non‑metformin monotherapy fails to adequately control blood glucose levels?
Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides?
Self-monitoring of blood glucose levels: What is the optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes?
Effectiveness of SGLT2 inhibitors for different ethnic groups: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups?
Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?